Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele
- PMID: 20385913
- PMCID: PMC2943432
- DOI: 10.1001/archneurol.2010.30
Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele
Abstract
Objective: To investigate with fluorodeoxyglucose positron emission tomography whether regional reductions in the cerebral metabolic rate for glucose (CMRgl) previously found in cognitively healthy late-middle-aged apolipoprotein E (APOE) epsilon4 carriers extend to members of the Latino Mexican American community.
Design: Prospective cohort study.
Setting: Banner Alzheimer's Institute, Phoenix, Arizona.
Patients or other participants: Eleven APOE epsilon4 carriers and 16 noncarriers from Arizona's Latino community (mean [SD] age, 54.6 [6.4] years) matched for sex, mean age, and educational level and who were predominantly of self-designated Mexican origin.
Main outcome measure: A brain mapping algorithm was used to compare cross-sectional regional CMRgl in Latino APOE epsilon4 carriers vs noncarriers.
Results: Participant groups had similar distributions for age, sex, education, family history of dementia, clinical ratings, and neuropsychological test scores. Latino APOE epsilon4 carriers had lower CMRgl than the noncarriers in the posterior cingulate, precuneus, and parietal regions previously found to be preferentially affected in patients with Alzheimer disease (AD) and cognitively healthy non-Latino APOE epsilon4 carriers. Additionally, the Latino APOE epsilon4 carriers had lower CMRgl in the middle and anterior cingulate cortex, hippocampus, and thalamus.
Conclusions: This study provides support for the relationship between APOE epsilon4 and risk of AD in Latino individuals. It illustrates the role of positron emission tomography as a presymptomatic endophenotype for the assessment of AD risk factors and supports the inclusion of Latino APOE epsilon4 carriers in proof-of-concept studies using fluorodeoxyglucose PET to evaluate promising presymptomatic treatments in cognitively healthy carriers of this common AD susceptibility gene.
Figures
Similar articles
-
18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.Neurobiol Aging. 2014 Sep;35(9):2096-106. doi: 10.1016/j.neurobiolaging.2014.03.006. Epub 2014 Mar 11. Neurobiol Aging. 2014. PMID: 24702820 Free PMC article.
-
Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging.Neuroimage. 2010 Jan 1;49(1):169-76. doi: 10.1016/j.neuroimage.2009.07.025. Epub 2009 Jul 23. Neuroimage. 2010. PMID: 19631758 Free PMC article.
-
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9. doi: 10.1073/pnas.061509598. Proc Natl Acad Sci U S A. 2001. PMID: 11248079 Free PMC article.
-
Age, APOE and sex: Triad of risk of Alzheimer's disease.J Steroid Biochem Mol Biol. 2016 Jun;160:134-47. doi: 10.1016/j.jsbmb.2016.03.012. Epub 2016 Mar 8. J Steroid Biochem Mol Biol. 2016. PMID: 26969397 Free PMC article. Review.
-
Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.Neuropsychol Rev. 2014 Sep;24(3):290-9. doi: 10.1007/s11065-014-9263-8. Epub 2014 Aug 22. Neuropsychol Rev. 2014. PMID: 25146994 Review.
Cited by
-
Impact of SORL1 genetic variations on MRI markers in non-demented elders.Oncotarget. 2016 May 31;7(22):31689-98. doi: 10.18632/oncotarget.9300. Oncotarget. 2016. PMID: 27177090 Free PMC article.
-
Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease.Brain Pathol. 2016 Sep;26(5):607-17. doi: 10.1111/bpa.12401. Brain Pathol. 2016. PMID: 27327656 Free PMC article. Review.
-
Mechanisms linking brain insulin resistance to Alzheimer's disease.Dement Neuropsychol. 2015 Apr-Jun;9(2):96-102. doi: 10.1590/1980-57642015DN92000003. Dement Neuropsychol. 2015. PMID: 29213950 Free PMC article. Review.
-
Using biomarkers to improve detection of Alzheimer's disease.Neurodegener Dis Manag. 2011 Apr;1(2):127-139. doi: 10.2217/NMT.11.11. Neurodegener Dis Manag. 2011. PMID: 22076127 Free PMC article.
-
Reversal of neurovascular coupling in the default mode network: Evidence from hypoxia.J Cereb Blood Flow Metab. 2021 Apr;41(4):805-818. doi: 10.1177/0271678X20930827. Epub 2020 Jun 14. J Cereb Blood Flow Metab. 2021. PMID: 32538282 Free PMC article. Clinical Trial.
References
-
- Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989;262:2551–2556. - PubMed
-
- Day JC. Population projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050. In: U.S.Bureau of the Census, editor. Current Population Reports. Washington,DC: U.S. Government Printing Office; 1996. pp. 25–1130.
-
- Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122. - PubMed
-
- Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56:49–56. - PubMed
-
- Clark CM, DeCarli C, Mungas D, et al. Earlier Onset of Alzheimer Disease Symptoms in Latino Individuals Compared With Anglo Individuals. Arch Neurol. 2005;62:774–778. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous